Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xoma has terminated its agreement with Zephyr Sciences for the research, development and commercialization of products related to bactericidal/permeability-increasing protein, including its Neuprex product.
Subscribe to our email newsletter
John Castello, chairman, president and CEO of Xoma commented, “Although Zephyr has devoted both time and effort toward the advancement of BPI, they have not met the financing requirements of our agreement and this led to our decision to terminate the relationship”.
“BPI’s excellent safety profile continues to be an attractive feature in clinical use as evidenced by its ongoing evaluation in both pediatric and adult indications, Xoma remains committed to the future development of BPI and is actively seeking new partnerships with private and public companies.”
BPI (bactericidal/permeability-increasing protein), a human protein found in certain white blood cells (neutrophils), is one of the body’s natural defenses against bacterial infections.